Lifechart, a full-stack gut wellness brand, has successfully raised approximately $250K from Prajay Advisors LLP, with Mumbai-based Cignas from NA Shah Advisors LLP acting as the transaction advisors to the deal. In addition to Prajay Advisors LLP, other investors i.e., Agility Ventures, Expert Dojo, and prominent angel investors such as Ahana Gautam, Nitish Mittersain - Founder of Nazara Technologies Pvt. Ltd., Sarath Sura - Founder of Sunn91 Ventures and Marwari Angels who have invested approximately $250K through convertible instruments were converted into equity in this round.
Gut health is fast becoming a priority in India, with 7 out of 10 Indians reportedly suffering from gut-related issues such as constipation, indigestion, fatty liver, piles, and acidity. Industry reports estimate that the global gut health market will reach $18 billion by 2025–26, and Lifechart is uniquely positioned to address this demand with its comprehensive diagnostic and treatment solutions.
Since its inception, Lifechart claims to have impacted over 250,000 customers, primarily from Tier 2, 3, and 4 cities across India, with its innovative approach to gut wellness. The brand’s full-stack solution offers an end-to-end experience from diagnosis to treatment, leveraging AI-driven technology and a network of highly trained medical professionals. Lifechart is in the process of hiring 50 in-house BAMS and BHMS doctors, expanding its capacity to address the growing demand for gut health solutions in underserved regions.
"We are proud to have attracted the trust of marquee investors, especially during a funding winter. The new capital will be used to enhance our AI capabilities, launch our proprietary diagnostic solutions, and build a new brand targeting Tier 1 cities," said Mukul Shah, CEO and Co-founder of Lifechart. "Our vision is not just to sell products, but to focus on diagnosing and treating gut health issues, which is a critical unmet need in India. This is what sets us apart from competitors."
In addition to scaling operations in smaller cities, Lifechart is set to launch India’s first plant-based microbiome-focused products specifically designed for the Tier 1 cities of India. These products will provide natural, holistic solutions, formulated by BAMS doctors, aimed at promoting better gut health. The company is also developing Gut Wellness kits, which will address common ailments such as constipation, fatty liver, piles, gas, and acidity.
To complement its human expertise, Lifechart is enhancing its proprietary AI engine, which is able to predict the geographical rise of gut diseases based on demographic factors and regional health patterns. This predictive model allows the company to fine-tune its service offerings and deliver more targeted and effective solutions.
"Through this funding, we will continue to expand our doctor network, enhance our AI model for better diagnosis, and launch India’s first gut wellness clinics and supermarkets in the coming years," added Mukul Shah. "Our customers trust us—our 42% month-on-month repeat rate is a testament to that. This new investment will allow us to accelerate our growth while maintaining our CM2 profitability."
Prakash Mody (Founder of Unichem Laboratory) and Jayendra Shah, Founders of Prajay LLP said in a joint statement that “Gut health is a growing concern not only in India but throughout the world. We are quite excited the way Lifechart with its unique technology & fullstack approach is solving this huge problem. We have full confidence in Mukul’s vision & execution abilities as he has been a serial entrepreneur in the past & has successfully built YoloBus (India’s leading Intercity Bus platform) & got it successfully acquired.”
Having been CM2 profitable for the past 12 months, Lifechart is now poised to three times its revenue in the coming year, backed by a steady stream of loyal customers and a business model centered on diagnostics and treatment rather than product sales alone.
The company plans to scale aggressively by opening 150 gut wellness clinics over the next three years, creating a more robust infrastructure for diagnosis and treatment across urban and rural India.Currently the company is in talks to raise another quick round of $1.5-$2 million via inbound interest of a well known VC firm from Delhi NCR to expand its fullstack model.